Preclinical Research

The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast […]

The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimerâs disease.

Janssen has formed a strategic collaboration with the drug discovery specialist that involves applying TargetAlloMod platforms to protein homeostasis.

A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.

Epistemic AI, Cincinnati Childrenâs Hospital Medical Center, and Boomer Esiason Foundation are working together to advance research into the rare disease.

The organization has given 29 research grants to scientists representing 17 different US institutions pursuing lymphoma treatments and cures in their work.

The organization has given 29 research grants to scientists representing 17 different US institutions pursuing lymphoma treatments and cures in their work.

A leader from market intelligence specialist Definitive Healthcare discusses the rise of precision medicine and the far-reaching benefits the field can yield.

The health care system and analytics company are joining on the ASAP study, a program that constitutes a five-year commitment to advancing cancer solutions.

The academic research center has adopted the life science technology companyâs cloud-based platform for cancer research, drug discovery, and clinical trials.

AstraZeneca is to acquire US-based blood cancer specialist, TeneoTwo, in a deal worth around US$1.27bn.

The Lifebit CloudOS will be employed to create a Federate Trusted Research Environment within the centerâs supercomputing cluster to handle data management.

The drug company, which uses artificial intelligence to discover and advance repurposed drugs, is harnessing the technology to find a treatment for Crohnâs.

The CRO has paired with the drug discovery technology firm on Logica, an artificial intelligence tool designed to accelerate development of new treatments.

Illumina has recently announced a 10-year-long strategic collaboration with Janssen Biotech, and a five-year partnership with Deerfield Management.

Leaders from the R&D tech company weigh in on how use of artificial intelligence has grown, ongoing challenges to effective adoption, and what lies ahead.

A leader from the health tech company explains how voice-based technologies could transform monitoring of patients with dementia, Alzheimerâs, and other conditions.

The one-year-old organization is giving $50m USD in grants to encourage scientists from five cancer research centers to work together on cancer solutions.

The biomarker developer is partnering with Alzheimer Center Amsterdam on decentralized assessment of patient cognition and function in preclinical research.

The US- and Hungary-based pharma firms will work on research, development, and commercialization of dopamine receptor modulators for potential treatments.

An executive from the AI specialist discusses how recent advances have provided opportunities for industry professionals to champion new ways of thinking.

The drug discovery firm will work with the Dean Felsher Laboratory, using the companyâs transomics platform to discover therapies for untreatable cancers.

The pharmaceutical companyâs Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a âstate-of-the-artâ facility.

The institute and the research/support organization will collaborate on development of novel therapies aimed at treating the central nervous system disorder.

Cullinan Oncology has formed a strategic partnership with the Icahn School of Medicine at Mount Sinai to research and develop targeted therapies for cancer.

The oncology centerâs Marie-JosÃe and Henry R. Kravis Cancer Ecosystems Project is intended to elevate the next generation of preclinical cancer research.

The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.

The pharmaceutical company reports studies have demonstrated the main protease inhibitor of Paxlovid maintains in vitro efficiency against the variant.

The researchers, in studying how polyps morph into colorectal cancer, have set a path for improved surveillance of the disease, harnessing precision medicine.

The collaboration will center on development of unique data sets, which could be used in helping promote better understanding of aspects of human health.

Clover Biopharmaceuticals, a clinical-stage biotech developing novel vaccines and biologic therapeutic candidates, has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical […]

An AI expert discusses progress in the field, gaps in understanding, and how predictive modeling and other advanced analytical tools could be put to use.

A leader from the R&D tech provider discusses the obstacles faced by drug development professionals in recent months, and ways they rose to the occasion.

Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in […]

According to a leader from Cytoreason, AI isnât necessarily the best or only tool suited to discover new and novel therapiesâit might take a human […]

The biotech firm has presented data from a study that could offer hope to patients with Parkinsonâs, Gaucher, Alzheimerâs and other neurodegenerative conditions.

A leader from the health tech solutions company explains how progress in genetic testing has helped advance the detection and prevention of breast cancer.

A new clinical trial of heterologous â or âmix-and-matchâ â combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research […]

AstraZeneca has built a new R&D facility – The Discovery Centre (DISC) – in Cambridge in the UK.

The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.

The company has deployed with several healthcare firms, emerged from stealth, named a chief commercial officer, and landed investors backing the technology.

The US agency plans to use the software firmâs Lighthouse technology to improve understanding of COVID-19 and other conditions in long-term care facilities.

The AI technology firm and pharma services company are joining to help one of the countryâs leading pharmaceutical firms develop a promising drug candidate.

An expert from the IRB and study solutions firm explains how advanced analytics can lead to several benefits, including shortened trial startup timelines.

The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.

Emerald Cloud Labâs remote, automated laboratory technology puts pieces of advanced scientific equipment within the reach of smaller research outfits.

The drug discovery company reportedly used AI-powered drug discovery to come up with a promising preclinical candidate for treatment of the kidney ailment.

The two firms will work together on solutions to connect de-identified, first-party data to real-world data to help advance precision medicine development.

Nanomeâs virtual reality tech is being put to use by Oak Ridge National Laboratory and top pharma firms to study COVID-19 and explore drug candidates.

The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.

The process management solutions firm says drug companies could use contract data to get a better handle on predicting demand and adjusting product output.

The genetic exome sequence analysis partnership has created a large database linking rare protein-coding genetic variants to human health and disease.

The organization, focused on building awareness and finding therapies for the rare disease, is boosting its annual research funding to more than $2.7m USD.

The project will use the artificial intelligence specialistâs cell-centered models and deconvolutions to gain insights for each individual asthma endotype.

An academic researcher and and company expert discuss on how evolving cryogenic electron microscopy has led to high resolutions and accelerated results.

The two organizations have formed a public-private partnership aimed at improving nonclinical research through better practices and standardization.

In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinsonâs cohort, to aid future research.

Created by an industry veteran with more than 20 yearsâ experience, Protodigm aims to offer innovation and expertise to pharmaceutical industry clients.

Sanofi and GSK have started the Phase 3 study for their COVID-19 vaccine candidate: eying up potential regulatory authorization in Q4, 2021.

The drug-discovery firm has partnered with several academic institutions to explore a Novartis lung-cancer treatmentâs potential in treating COVID-19.

The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.

The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.

New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment […]

The collaboration will enable Charles River clients to access Valenceâs artificial intelligence platform in their pharmaceutical development projects.

The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.

The US Food and Drug Administration (FDA) has issued guidance for companies developing vaccines, diagnostics and therapeutics against new variants of SARS-CoV-2.

The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas

In the drive to advance personalized medicine, researchers are increasingly turning to radiomics to assist in the discovery of new types of biomarkers.

The collaboration between the Jameel Clinic and pharma firm will harness artificial intelligence and machine learning in developing health solutions.

The UP.SIGHT single-sell dispensing system is designed to boost efficiency in cell-line development workflows and offer double assurance of clonality.

California information technology and services company Syntegra and the National Institutes of Health (NIH) have signed a partnership to ‘democratize access to the largest set […]

Sosei Heptares and PharmEnable will harness artificial intelligence-enabled technology and advanced chemistry to explore neurological disease solutions.

Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.

The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.

The two organizations will collaborate on development of synthetic arms for clinical studies, drawing from millions of patient records and trial subject.

Ovation.io will harness the funding to develop software and data products supporting drug discovery and development, creating diagnostics and more.

A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.

An executive from the digital biomarker tech company explains the myriad benefits of biomarker analysis in advancing precision health solutions.

Sanofi has made a new five-year, $25m partnership agreement with the World Health Organization (WHO) to fight Neglected Topical Diseases (NTD); and eliminate sleeping sickness […]

The resourceâdesigned to provide seed capital, lab space, offices and management consulting to researchersâis opening its doors earlier than expected.

The two companies plan to work together on technology that advances pharmacovigilance in order to increase safety and effectiveness of new therapies.

The global pharma firm will work with the digital mental health solutions specialist on solutions for treatment-resistant depressive order patients.

The two companies plan to work together on the creation a drug-development technology tool that helps in safety margin risk assessment prediction.

A leader from the AI technology firm discusses how life-sciences pros are harnessing AI to help continue their work in the face of the pandemic.

The company’s Spectus and Percepta platforms offer features to help researchers meet challenges associated with working and collaborating in the pandemic.

A leader from the CRO shares insights as to what strategies and philosophies work best when working to craft a successful drug development program.

Thermo Fisher Scientific will partner with AstraZeneca and the University of Nebraska Medical Center to advance biomarker discovery and characterization.

The drug discovery and pharma companies have extended their agreement to collaborate on development of new treatments for a range of therapeutic areas.

The newly expanded CentoMD 5.8 mutation database includes clinical, epidemiologic and phenotypic data from more than 430,000 analyzed cases.

The research taking place at Nationwide Childrenâs Hospital is seeking a treatment for a rare Duchenne muscular dystrophy mutation.

The research taking place at Nationwide Childrenâs Hospital is seeking a treatment for a rare Duchenne muscular dystrophy mutation.

A leader from the global CRO discusses how the companyâs research is fueled by partnerships and patient-centricity.

The AI-centric drug discovery technology firm is working with a foundation to discover potential treatments for the rare neurogenetic disorder.

Researchers at Novateur Ventures have released a strategy that examines leukotrienes as the cause for hyperinflammatory response in severe cases.

The company has landed $70m in Series C funding, with the purpose of accelerating development of cancer therapies with single-cell multiomics.

Neurasic Therapeutics is borne from a collaborative effort intended to advance development of opioid-alternative pain relief.

A leader from the health solutions and technology company explains how the proper biological models can enhance drug discovery and development.

The company is introducing technology using artificial intelligence and machine learning to accelerate drug discovery and development.

An innovation-minded nonprofit organization aims to foster collaboration among scientists and tech minds, to fuel discovery and accelerate therapies.

The two partners will use Dewpointâs platform, focusing on biomolecular condensates, to treat the disease.

The $800K grant will fund development of therapeutics for infectious diseases, including respiratory viruses like COVID-19, using machine learning.